{"doi":"10.1101/2025.04.08.647757","title":"Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice","abstract":"Summary Microdosing, the prolonged ingestion of psychedelics at sub-hallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT 2B receptors, which cause heart disease with strong chronic activation. We investigated the effects of microdosed psychedelics on cardiovascular health in mice using electrocardiography after chronically administering either serotonin as a positive control or lysergic acid diethylamide (LSD) at two sub-hallucinogenic doses. Serotonin produced significant ventricular thickening at 4- and 8-weeks. No significant changes were observed in vehicle or LSD groups. We determined the affinity and potency of LSD, psilocybin, and norfenfluramine at mouse and human 5-HT 2B Rs and observed no significant differences. We calculated that levels of 5-HT 2B activation by low-dose LSD were substantial, but short-lived, compared to the cardiotoxin d -fenfluramine. Together, these data provide no evidence of cardiovascular risk associated with prolonged administration of low-dose LSD in mice.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2025,"id":556148,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.951,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1402740,"name":"Serena S. Schalk","orcid":null,"position":1,"is_corresponding":false},{"id":1402168,"name":"Jillian L. King","orcid":"0000-0002-7274-8443","position":2,"is_corresponding":false},{"id":1455877,"name":"J.R. Strong","orcid":null,"position":3,"is_corresponding":false},{"id":1455878,"name":"Caden K. O’Connell","orcid":null,"position":4,"is_corresponding":false},{"id":1402742,"name":"Joselynn R. Calderon","orcid":null,"position":5,"is_corresponding":false},{"id":225472,"name":"John D. McCorvy","orcid":"0000-0001-7555-9413","position":6,"is_corresponding":false},{"id":395021,"name":"Scott M. Thompson","orcid":"0000-0001-9844-9049","position":7,"is_corresponding":false},{"id":932762,"name":"Devin P. Effinger","orcid":"0000-0002-9125-860X","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:55:08.896385Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}